BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31668800)

  • 1. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
    Bolan PO; Zviran A; Brenan L; Schiffman JS; Dusaj N; Goodale A; Piccioni F; Johannessen CM; Landau DA
    Cell Syst; 2020 Jan; 10(1):52-65.e7. PubMed ID: 31668800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
    Quintanal-Villalonga A; Molina-Pinelo S; Cirauqui C; Ojeda-Márquez L; Marrugal Á; Suarez R; Conde E; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
    J Thorac Oncol; 2019 Apr; 14(4):641-655. PubMed ID: 30639621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.
    Lee PH; Chang GC
    Clin Lung Cancer; 2021 Jul; 22(4):e536-e541. PubMed ID: 32839131
    [No Abstract]   [Full Text] [Related]  

  • 5. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
    J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
    Xie Z; Gu Y; Xie X; Lin X; Ouyang M; Qin Y; Zhang J; Lizaso A; Chen S; Zhou C
    Clin Lung Cancer; 2021 May; 22(3):e390-e394. PubMed ID: 32693944
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
    Yang X; Huang C; Chen R; Zhao J
    Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
    [No Abstract]   [Full Text] [Related]  

  • 11. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
    Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
    Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
    Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
    Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
    Starrett JH; Guernet AA; Cuomo ME; Poels KE; van Alderwerelt van Rosenburgh IK; Nagelberg A; Farnsworth D; Price KS; Khan H; Ashtekar KD; Gaefele M; Ayeni D; Stewart TF; Kuhlmann A; Kaech SM; Unni AM; Homer R; Lockwood WW; Michor F; Goldberg SB; Lemmon MA; Smith PD; Cross DAE; Politi K
    Cancer Res; 2020 May; 80(10):2017-2030. PubMed ID: 32193290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
    La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
    J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
    Eberlein CA; Stetson D; Markovets AA; Al-Kadhimi KJ; Lai Z; Fisher PR; Meador CB; Spitzler P; Ichihara E; Ross SJ; Ahdesmaki MJ; Ahmed A; Ratcliffe LE; O'Brien EL; Barnes CH; Brown H; Smith PD; Dry JR; Beran G; Thress KS; Dougherty B; Pao W; Cross DA
    Cancer Res; 2015 Jun; 75(12):2489-500. PubMed ID: 25870145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response
    Foggetti G; Li C; Cai H; Hellyer JA; Lin WY; Ayeni D; Hastings K; Choi J; Wurtz A; Andrejka L; Maghini DG; Rashleigh N; Levy S; Homer R; Gettinger SN; Diehn M; Wakelee HA; Petrov DA; Winslow MM; Politi K
    Cancer Discov; 2021 Jul; 11(7):1736-1753. PubMed ID: 33707235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib and Trametinib in Patients With
    Luo J; Makhnin A; Tobi Y; Ahn L; Hayes SA; Iqbal A; Ng K; Arcila ME; Riely GJ; Kris MG; Yu HA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
    Poels KE; Schoenfeld AJ; Makhnin A; Tobi Y; Wang Y; Frisco-Cabanos H; Chakrabarti S; Shi M; Napoli C; McDonald TO; Tan W; Hata A; Weinrich SL; Yu HA; Michor F
    Nat Commun; 2021 Jun; 12(1):3697. PubMed ID: 34140482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
    Takahashi S; Noro R; Seike M; Zeng C; Matsumoto M; Yoshikawa A; Nakamichi S; Sugano T; Hirao M; Matsuda K; Hamada M; Gemma A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.